January 16, 2020
TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China
Non-profit drug developer partners with leading manufacturer of Tuberculosis (TB) medicine in China
November 13, 2019
Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 6, 2019
Global Health Innovators Come Together to Identify Ways to Further Strengthen European Investment in Global Health Research & Innovation
October 28, 2019
TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid
October 28, 2019
TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Non-profit product development partnership and generic manufacturer agree to produce new TB drug for countries with high incidence of TB
October 17, 2019
With One and a Half Million People Dying from TB Every Year, It’s Time to Accelerate Progress
Statement from TB Alliance on WHO Global TB Report 2019
September 23, 2019
TB Alliance Statement on TB REACH Wave 7
A Welcome Investment in TB Treatment
August 14, 2019
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB
July 18, 2019